Добірка наукової літератури з теми "Antibody-toxin conjugates – theraputic use"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Зміст
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Antibody-toxin conjugates – theraputic use".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Antibody-toxin conjugates – theraputic use"
Senter, Peter D., Marilyn J. Tansey, John M. Lambert, and Walter A. Blattler. "NOVEL PHOTOCLEAVABLE PROTEIN CROSSLINKING REAGENTS AND THEIR USE IN THE PREPARATION OF ANTIBODY-TOXIN CONJUGATES." Photochemistry and Photobiology 42, no. 3 (September 1985): 231–37. http://dx.doi.org/10.1111/j.1751-1097.1985.tb08936.x.
Повний текст джерелаKIEREK-JASZCZUK, DANUTA, RONALD R. MARQUARDT, and DAVID ABRAMSON. "Use of a Heterologous Solid-Phase Antigen in an Indirect Competitive Antibody-Capture Enzyme-Linked Immunosorbent Assay for T-2 Mycotoxin." Journal of Food Protection 60, no. 3 (March 1, 1997): 321–27. http://dx.doi.org/10.4315/0362-028x-60.3.321.
Повний текст джерелаLefeber, Dirk J., Barry Benaissa-Trouw, Johannes F. G. Vliegenthart, Johannis P. Kamerling, Wouter T. M. Jansen, Kees Kraaijeveld, and Harm Snippe. "Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to Streptococcus pneumoniae Type 3." Infection and Immunity 71, no. 12 (December 2003): 6915–20. http://dx.doi.org/10.1128/iai.71.12.6915-6920.2003.
Повний текст джерелаChen, Zhaochun, Rachel Schneerson, Julie A. Lovchik, Zhongdong Dai, Joanna Kubler-Kielb, Liane Agulto, Stephen H. Leppla, and Robert H. Purcell. "Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax." Clinical and Vaccine Immunology 22, no. 8 (June 3, 2015): 902–8. http://dx.doi.org/10.1128/cvi.00137-15.
Повний текст джерелаNiculescu-Duvaz, I., and C. J. Springer. "Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A Targeting Strategy in Cancer Chemotherapy." Current Medicinal Chemistry 2, no. 3 (October 1995): 687–706. http://dx.doi.org/10.2174/092986730203220223143057.
Повний текст джерелаTedder, T. F., V. S. Goldmacher, J. M. Lambert, and S. F. Schlossman. "Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system." Journal of Immunology 137, no. 4 (August 15, 1986): 1387–91. http://dx.doi.org/10.4049/jimmunol.137.4.1387.
Повний текст джерелаAkter, Sultana, Teemu Kustila, Janne Leivo, Gangatharan Muralitharan, Markus Vehniäinen, and Urpo Lamminmäki. "Noncompetitive Chromogenic Lateral-Flow Immunoassay for Simultaneous Detection of Microcystins and Nodularin." Biosensors 9, no. 2 (June 18, 2019): 79. http://dx.doi.org/10.3390/bios9020079.
Повний текст джерелаLu, Ying-Jie, Sophie Forte, Claudette M. Thompson, Porter W. Anderson, and Richard Malley. "Protection against Pneumococcal Colonization and Fatal Pneumonia by a Trivalent Conjugate of a Fusion Protein with the Cell Wall Polysaccharide." Infection and Immunity 77, no. 5 (March 2, 2009): 2076–83. http://dx.doi.org/10.1128/iai.01554-08.
Повний текст джерелаPestka, James J. "Enhanced Surveillance of Foodborne Mycotoxins by Immunochemical Assay." Journal of AOAC INTERNATIONAL 71, no. 6 (November 1, 1988): 1075–81. http://dx.doi.org/10.1093/jaoac/71.6.1075.
Повний текст джерелаPui, CH, FG Behm, and WM Crist. "Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia." Blood 82, no. 2 (July 15, 1993): 343–62. http://dx.doi.org/10.1182/blood.v82.2.343.343.
Повний текст джерелаДисертації з теми "Antibody-toxin conjugates – theraputic use"
Ng, Wai-yun Louisa, and 吳慧欣. "Production of variants of mitogillin with reduced IgE bindingactivity." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31972093.
Повний текст джерела"Construction of a Recombinant Immunotoxin." University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/2100/270.
Повний текст джерела"Construction of a recombinant immunotoxin." Thesis, University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/10453/20069.
Повний текст джерелаIn recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology. In general, this involves fusion of a toxin gene with sequence encoding a variety of clinically relevant proteins or peptides. Using these techniques a recombinant immunotoxin has been engineered by fusing the genes encoding an antibody fragment with the sequence of a small cytolytic peptide, melittin. The antibody fragment consists of the antigen binding site derived from a murine monoclonal antibody K- 1-21, which binds to human free kappa light chains and recognises a specific epitope (KMA) expressed on the surface of human myeloma and lymphoma cells. The toxic portion of the molecule is melittin, a 26 amino acid, membrane lytic peptide which is a major component of bee venom. Using PCR a single chain Fv (scFv) was constructed by linking VH and VL genes with an oligonucleotide encoding a flexible, hydrophilic peptide. The melittin gene was synthesised as an oligonucleotide and extended by PCR. Nucleotide sequence encoding a linker peptide was added to the 5' end and a primer encoding a FLAG peptide was used to extend the 3' end. This gene construct was then ligated into the recombinant expression vector, pPOW scFv, to create the fusion gene encoding the recombinant immunotoxin. The gene construct was expressed in the periplasm of E.coli (TOPP2) using the secretion signal pelB . Expression of the foreign protein was monitored by western blot using a monoclonal antibody which recognises the FLAG peptide encoded at the carboxy terminal region of the gene construct. Expression of the recombinant immunotoxin was optimised and the resulting protein was purified using anti-FLAG M2 affinity chromatography. Antigen binding activity was assessed by ELISA and flow cytometry using a human myeloma cell line, HMy2, which expresses the KMA antigen.Binding of the immunotoxin to a control human cell line, K562, which does not express KMA on the cell surface was also assessed. The results indicated that the recombinant immunotoxin retained antigen binding specificity and it was cytotoxic towards the target cell line (HMy2).
Книги з теми "Antibody-toxin conjugates – theraputic use"
Ramakrishnan, S. Cytotoxic conjugates. Austin: R.G. Landes Co., 1993.
Знайти повний текст джерела1960-, Tyle Praveen, and Ram Bhanu P. 1951-, eds. Targeted therapeutic systems. New York: Dekker, 1990.
Знайти повний текст джерела1947-, Wiley Ronald G., and Lappi Douglas A, eds. Molecular neurosurgery with targeted toxins. Totowa, N.J: Humana Press, 2005.
Знайти повний текст джерелаImmunotoxin Methods and Protocols. Humana Press, 2001.
Знайти повний текст джерелаFrankel, A. Clinical Applications of Immunotoxins (Current Topics in Microbiology and Immunology). Springer-Verlag Telos, 1998.
Знайти повний текст джерелаCarl-Wilhelm, Vogel, ed. Immunoconjugates: Antibody conjugates in radioimaging and therapy of cancer. New York: Oxford University Press, 1987.
Знайти повний текст джерелаAntibodydrug Conjugates And Immunotoxins From Preclinical Development To Therapeutic Applications. Springer, 2012.
Знайти повний текст джерела1927-, Baldwin R. W., Byers Vera S, and Mann Ronald D. 1928-, eds. Monoclonal antibodies and immunoconjugates. Carnforth, Lancs, UK: Parthenon Pub. Group, 1990.
Знайти повний текст джерелаW, Baldwin R., Byers Vera S, and Mann R. D. 1928-, eds. Monoclonal antibodies and immunoconjugates in cancer treatment. Carnforth: Parthenon Publishing, 1990.
Знайти повний текст джерела1935-, Quash Gerard A., Rodwell John D. 1946-, Institut national de la santé et de la recherche médicale (France), and CYTOGEN Corporation, eds. Covalently modified antigens and antibodies in diagnosis and therapy. New York: Dekker, 1989.
Знайти повний текст джерела